Our Technology

Providing ''Gold Standard'' in COPD Assays

ProteaseTag® Technology

ProAxsis has developed a range of unique molecules, known as ProteaseTags ®, which have the capacity to rapidly and selectively bind active proteases, including those which are biomarkers of diagnostic and prognostic value.

ProteaseTags ® rapidly provide a visual readout of active proteases in complex biological samples with a high level of specificity and selectivity. In diseases characterised by abnormal protease action including but not limited to COPD, Bronchiectasis and Cystic Fibrosis. ProteaseTag ® test systems have the potential to be incorporated into Point of Care tests, Companion Diagnostics, and activity-based immunoassays.

Our technology 3

Active Neutrophil Elastate Explained 

Proteases are a large grouping of biological molecules that play pivotal regulatory roles in most physiological processes required for life.

Unregulated protease activity (which occurs when the normal control of their action is lost) can be a trigger of many important human diseases thereby making active proteases important.

Therapeutic Targets and Biomarkers of Disease Activity

Standard methods of detection and quantification of active proteases are based on the hydrolysis of chromogenic or fluorogenic peptide substrates. Biological samples contain multiple activities with the potential to hydrolyse these substrates and are not sufficiently selective for biomarker studies.

Typical antibody-based systems e.g. ELISA (Enzyme-linked ImmunoSorbent Assay) will only detect total protein with no indication of the fraction associated with the active form of the enzyme.
Our technology 1

Industry and Peer Recognition

ATS logo 1
The New England Journal of Medicine

“I have had the opportunity to see for myself  the impressive set-up of the laboratory and offices. Under a dynamic management team, there is the opportunity to serve the much larger U.S. market…….Prospects are bright.”

Eric Evans,
Executive Committee,
Mass Medical Angels, Boston

“I am excited with the highly innovative ProteaseTag® technology, as there remains a clear unmet need for additional novel diagnostic tools within Respiratory Medicine.”

Prof. Mona Bafadhel,
Kings, London

“This assay performed exceptionally well in the Performance Evaluation study which analysed >1,100 clinical serology samples demonstrating levels of sensitivity and specificity of 100% and 99.3% respectively, which was extremely impressive.”

Prof. Tara Moore,

“Measuring Active NE levels using ProteaseTag® technology can identify bronchiectasis patients with airway bacterial infection and those patients at high risk of  exacerbations over the subsequent 12 months.”

Prof. Amelia Shoemark,